SB5 adalimumab biosimilar in the treatment of psoriasis and psoriatic arthritis
- 1 May 2020
- journal article
- letter
- Published by Hindawi Limited in Dermatologic Therapy
- Vol. 33 (3)
- https://doi.org/10.1111/dth.13435
Abstract
Click on the article title to read more.This publication has 7 references indexed in Scilit:
- AURIEL ‐PsO: a randomized, double‐blind phase III equivalence trial to demonstrate the clinical similarity of the proposed biosimilar MSB 11022 to reference adalimumab in patients with moderate‐to‐severe chronic plaque‐type psoriasisBritish Journal of Dermatology, 2019
- Clinical experience with the etanercept biosimilar SB4 in psoriatic patientsInternational Journal of Clinical Pharmacy, 2019
- Switching From Reference Adalimumab to SB5 (Adalimumab Biosimilar) in Patients With Rheumatoid ArthritisArthritis & Rheumatology, 2018
- Clinical experience with infliximab biosimilar in psoriasisBritish Journal of Dermatology, 2017
- Phase III Randomized Study of SB5, an Adalimumab Biosimilar, Versus Reference Adalimumab in Patients With Moderate‐to‐Severe Rheumatoid ArthritisArthritis & Rheumatology, 2017
- Clinical similarity of biosimilar ABP 501 to adalimumab in the treatment of patients with moderate to severe plaque psoriasis: A randomized, double-blind, multicenter, phase III studyJournal of the American Academy of Dermatology, 2017
- The clinical features of rheumatoid arthritisEuropean Journal of Radiology, 1998